IN10018 with dalpiciclib for meningiomas that keep growing
Original title: IN10018 in Combination With Dalpiciclib for Progressive Meningiomas
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, mainly to check safety and find the right dose.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests two drugs, taken by mouth, in adults whose meningioma has kept growing or has come back.
Who this trial is for. This trial is for adults with a progressive meningioma. That is a tumor in the layers around the brain that has kept growing or returned after earlier treatment. People in the study take two drugs by mouth, IN10018 and dalpiciclib, in 28-day cycles.
Where it stands. The trial has not reported results. The main goals are to check side effects and find a dose of the two drugs to use in future studies. Researchers will also look at whether the treatment can shrink tumors or slow their growth, how the body handles the drugs, and markers in tumor and blood. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If your meningioma keeps growing, this is one study you could ask your care team about. They can help you think through whether it fits your situation. Only the trial team decides who can take part.
What it doesn't mean: This does not mean the two drugs work. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, August 7, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.